18,420 Shares in Moderna, Inc. $MRNA Bought by Cresset Asset Management LLC

Key Points

• Cresset Asset Management LLC has invested $522,000 in a new position in Moderna, Inc., acquiring 18,420 shares as reported in their recent 13F filing.
• Moderna's stock has a current price of $27.12, with a market cap of $10.55 billion and a price-to-earnings ratio of -3.60.
• Despite a challenging earnings report with a negative return on equity of 25.96%, Moderna's revenue exceeded analysts' expectations, contributing to a consensus rating of "Hold" from several analysts.

Cresset Asset Management LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 18,420 shares of the company's stock, valued at approximately $522,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Itau Unibanco Holding S.A. boosted its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its holdings in shares of Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Moderna by 11.4% in the 1st quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after purchasing an additional 451 shares in the last quarter. Blue Sky Capital Consultants Group Inc. boosted its holdings in shares of Moderna by 3.8% in the 1st quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company's stock worth $429,000 after purchasing an additional 556 shares in the last quarter. Finally, Empirical Finance LLC boosted its holdings in shares of Moderna by 7.3% in the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company's stock worth $261,000 after purchasing an additional 624 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MRNA shares. Bank of America lowered their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research note on Friday, August 1st. Citigroup started coverage on Moderna in a research note on Friday, August 1st. They issued a "neutral" rating and a $40.00 target price for the company. UBS Group lowered their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, William Blair reissued a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Stock Performance

Shares of Moderna stock traded down $0.70 during midday trading on Thursday, hitting $24.40. The company had a trading volume of 7,104,338 shares, compared to its average volume of 10,722,049. The stock has a market capitalization of $9.49 billion, a P/E ratio of -3.24 and a beta of 1.83. The company has a 50 day moving average of $29.14 and a 200 day moving average of $28.94. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $79.96.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's revenue was down 41.1% compared to the same quarter last year. During the same period last year, the business posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.